I haven't seen any data on the cognitive endpoint, in the 10mg dose either, but have been told it showed a trend. I believe CYPB did see all data before taking such a big decision. I thought the data were good since the study was powered to show statistical significance vs placebo and not Risperidone. BiolineRx investors weren't so happy with the deal as they were hoping for a big pharma partner (but then they were not happy when PLX partnered with a big pharma cause they were hoping the company will be bought...)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.